Chemoinformaics analysis of 1,3,9-Trihydroxycoumestan
| Molecular Weight | 284.223 | nRot | 0 |
| Heavy Atom Molecular Weight | 276.159 | nRig | 21 |
| Exact Molecular Weight | 284.032 | nRing | 4 |
| Solubility: LogS | -3.83 | nHRing | 2 |
| Solubility: LogP | 3.026 | No. of Aliphatic Rings | 0 |
| Acid Count | 0 | No. of Aromatic Rings | 4 |
| Base Count | 0 | No. of Aliphatic Carbocycles Rings | 0 |
| Atoms Count | 29 | No. of Aliphatic Hetero Cycles | 0 |
| No. of Heavy Atom | 21 | No. of Aromatic Carbocycles | 2 |
| nHetero | 6 | No. of Aromatic Hetero Cycles | 2 |
| nBridge Head | 0 | No. Saturated Carbocycles | 0 |
| No. of Hydrogen atom | 8 | No. of Saturated Hetero Cycles | 0 |
| No. of Carbon atom | 15 | No. of Saturated Rings | 0 |
| No. of Nitrogen atom | 0 | No. of Arom Atom | 17 |
| No. of Oxygen atom | 6 | No. of Arom Bond | 20 |
| nHA | 6 | APOL | 35.1963 |
| nHD | 3 | BPOL | 12.3657 |
| QED | 0.429 |
| Synth | 2.666 |
| Natural Product Likeliness | 1.408 |
| NR-PPAR-gamma | 0.951 |
| Lipinski | Accepted |
| Pfizer | Accepted |
| GSK | Accepted |
| Golden Triangle | Accepted |
| Pgp-inh | 0.002 |
| Pgp-sub | 0.965 |
| HIA | 0.04 |
| CACO-2 | -5.022 |
| MDCK | 0.00001 |
| BBB | 0.008 |
| PPB | 0.919929 |
| VDSS | 0.701 |
| FU | 0.12468 |
| CYP1A2-inh | 0.99 |
| CYP1A2-sub | 0.419 |
| CYP2c19-inh | 0.175 |
| CYP2c19-sub | 0.053 |
| CYP2c9-inh | 0.621 |
| CYP2c9-sub | 0.954 |
| CYP2d6-inh | 0.704 |
| CYP2d6-sub | 0.611 |
| CYP3a4-inh | 0.416 |
| CYP3a4-sub | 0.064 |
| CL | 8.408 |
| T12 | 0.869 |
| hERG | 0.005 |
| Ames | 0.335 |
| ROA | 0.049 |
| SkinSen | 0.902 |
| Carcinogencity | 0.063 |
| EI | 0.942 |
| Respiratory | 0.131 |
| NR-Aromatase | 0.867 |
| Antiviral | Yes |
| Prediction | 0.584111 |